Table Of Content

CUMULATIVE INDEX 1996 Volume2 5 March GASTROINTESTINAL MOTILITY IN CLINICAL PRACTICE, pages 1-266 June NSAIDS, EICOSANOIDS, AND THE GASTROENTERIC TRACT, pages 267-433 September PARASITIC DISEASES OF THE LIVER AND INTESTINES, pages 435-715 December COLORECTAL NEOPLASIA, PART I: THE SCIENTIFIC BASIS FOR CURRENT MANAGEMENT, pages 717-878 Note: Page numbers of article titles are in bold face type. Abdominal pain, in pediatric patients, a,-Adrenoreceptor agonists, in motility 212-213 disorders, 234-235 Aberrant crypt foci, in colorectal cancer, Aganglionosis (Hirschsprung’s disease), in 739-740 pediatric patients, 219-220 assay for, 827 neuropathy in, 189-190, 195 Abscess, liver, amebic, 478-479, 481, Age, vs. NSAID injury risk, 384 483-484 AIDS. See Human immunodeficiency virus in ascariasis, 566-567 infection. Acalculous cholecystitis, in ascariasis, 566 Albendazole, in ascariasis, 573 in cryptosporidiosis, 694 in capillariasis, 585 Acetaminophen, in colorectal cancer in echinococcosis, 670, 679-683 inhibition, 779-781 in giardiasis, 507 poisoning from, liver injury in, isopros- Alcohol use, colorectal cancer risk and, 725 tane measurement in, 422 liver disease in, isoprostane measure- Acetazolamide, in altitude sickness, 465 ment in, 421 Alginic acid, in gastroesophageal reflux, 80 Acetylsalicylic acid, in colorectal cancer Alkylating agents, tolerance of, in inhibition, 828 mismatch repair-deficient cells, Achalasia, cricopharyngeal, 42-43, 46 760-761 in Chagas’ disease, 188 Allergy, in giardiasis, 504 manometry in, 60-61 Allopurinol, in American trypanosomiasis, Acid, reflux of. See Gastroesophageal reflux. 521 Acid perfusion test, in gastroesophageal in visceral leishmaniasis, 544 reflux, in noncardiac chest pain, 84-85 Altitude sickness, 465 Acquired immunodeficiency syndrome. Alveolar echinococcosis. See under See Human immunodeficiency virus Echinococcosis. infection. Amebiasis, 471-492 Adaptation, to NSAID toxicity, 280, 286 causative agent of (Entamoeba histolytica), Adenomas, of colon. See under Colon. identification of, 480 Adhesive interactions, in colorectal cancer interactions with intestine, 473-476 metastasis, at primary site, 808-810 life cycle of, 471-472 at target organ, 811-814 metabolism of, 476 860 CUMULATIVE INDEX 1996 Amebiasis (Continued) manometry of, 171-172, 174 vs. Entamoeba dispar, 472-473, 484-485 APC gene, mutations of, in colorectal clinical features of, 478-480 cancer, 741-744 diagnosis of, 480-481 in familial adenomatous polyposis, epidemiology of, 472-473 796 host immunity in, 477-478 Apoptosis, induction of, NSAIDs in, 830 immunization for, 484 Appendix, ascariasis of, 562-563 in pregnancy, 484 Arachidonic acid, metabolism of, 267-270. invasive, 482-483 See also Eicosanoids; Isoprostanes; noninvasive, 483-484 Leukotrienes; Prostaglandin(s); of liver, 478-479, 481, 483-484 Thromboxanes. pathogenesis of, 473-478 in inflammatory bowel disease, prevention of, 484 325-326 risk factors for, 473 inflammation and, 319-326 treatment of, 482-485 Ascariasis, 553-577 Ameboma, 478 appendicular, 562-563 American trypanosomiasis. See causative agent of (Ascaris lumbricoides), Trypanosomiasis, American. 553-554 Amphotericin B, in visceral leishmaniasis, eggs of, 554-555 544 identification of, 572 Ancylostoma caninum infections life cycle of, 555-557 (hookworm), 585-588 migration of, 557 Anemia, in hookworm disease, 586 morphology of, 554-555 in trichuriasis, 591 classification of, 553-554 Angina pectoris, vs. noncardiac chest pain, definition of, 553 84 diagnosis of, 572 Angiogenesis, in cancer metastasis, epidemiology of, 557-558 806-808 hepatobiliary, 563-570 Anorectal and pelvic floor function, historic aspects of, 554 163-182 intensity of, 558 anatomic aspects of, 163-167 intestinal, 560-562 in constipation, 174-176 morbidity and mortality in, 558-559 in fecal continence, 167-169 pancreatic, 563-570 in fecal incontinence, 169-173 peritoneal, 562 in obstructed defecation, 176-177 prevention of, in community, 574 innervation in, 164-166 pulmonary, 557, 559-560 rectoanal inhibitory reflex in, 167 pyogenic cholangitis and, 570-571 Antacids, in gastroesophageal reflux, 80 reinfection in, 558 Anticarcinogens, in diet, 721-723 Anticoagulants, NSAIDs with, toxicity of, transmission of, 555-556 386-387 treatment of, 572-574 Antidiarrheal agents, colonic motility Ascorbic acid (vitamin C), in colorectal effects of, 159 cancer inhibition, 839-840 Anti-inflammatory drugs in, in colorectal Aspiration, of echinococcal cysts, 668-669 cancer chemoprevention, 828-834. See Aspirin, dose of, vs. ulcer risk, 385 also under Nonsteroidal anti- in colorectal cancer inhibition, 335-344, inflammatory drugs. 728-729, 829-831 Antimonial drugs, in visceral animal studies of, 774-775 leishmaniasis, 544-545 clinical trials of, 785-786 Antioxidants, colorectal cancer risk and, molecular targets of, 786-787 722, 835-841 observational studies of, 781-784 Antireflux mechanism, fluoroscopic in familial adenomatous polyposis, ani- studies of, 54-55 mal studies of, 353 Antireflux surgery, in gastroesophageal prophylactic, injury from, vs. cardiovas- reflux, 81, 90-91 cular risks, 302-303 Antispasmodics, in motility disorders, toxicity of, 288 233-234 Asthma, gastroesophageal reflux and, Antroduodenal manometry, in small 86-91 intestinal motility assessment, 123-124 clinical features of, 87 Anus. See also Anorectal and pelvic floor esophageal testing in, 87-88 function. treatment of, 88, 90-91 CUMULATIVE INDEX 1996 861 Attenuated adenomatous polyposis coli, Breast cancer, colorectal cancer risk in, 729 795-796 Bulimic vomiting, psychopathology of, 23 Auerbach’s plexus, anatomy of, 183-184 Autonomic neuropathy, gastric motility disorders in, 130 Azapropazone, injury from, risks of, 386 Cadherins, in colorectal cancer metastasis, 809 Cajal, interstitial cells of, 186-187 Calcium, colorectal cancer risk and, 725, Bacille Calmette-Guérin, in visceral 834-835 leishmaniasis, 545 Calcium channel blockers, in motility Bacteremia, in schistosomiasis, 610 disorders, 235 Bacterial overgrowth syndromes, small Cancer, breast, colorectal cancer risk in, intestinal motility disorders in, 729 137-138, 237-238 colorectal. See Colorectal cancer. Balloon expulsion test, in constipation, 174 esophageal, NSAID inhibition of, 343 Barium studies, in gastroesophageal reflux, gastric, NSAID inhibition of, 343 77, 87-88 in schistosomiasis, 609-610 in oropharyngeal dysphagia, 38-39 prevention of, levels of, 821-822 of small intestinal motility, 122-123 Capillariasis, 583-585 Barostat, in motility assessment, colonic, Carbon tetrachloride toxicity, isoprostanes 152-153 in, 417-418 gastric, 122 Carcinoembryonic antigen, in colorectal in pediatric patients, 212 cancer metastasis, 810, 813 Basement membrane, disruption of, in Carcinogenesis, eicosanoids in, 357 colorectal cancer metastasis, 810-811 in colorectal cancer, histologic progres- Beef tapeworm, 638-644 sion in, 738-740 Benznidazole, in American model for, 749-750 trypanosomiasis, 520-521 stages of, 823-824 Bernstein (acid perfusion) test, in Carcinoma, of larynx, in gastroesophageal gastroesophageal reflux, in noncardiac reflux, 94 chest pain, 84-85 Cardiopathy, in American Bertiella studeri (tapeworm), 650 trypanosomiasis, 521-523 Beta-carotene, in colorectal cancer Carotenoids, in colorectal cancer inhibition, 837-839 inhibition, 837-839 Bethanechol, in gastroesophageal reflux, 80 CD44 molecule, in colorectal cancer Bile salts, colorectal cancer risk and, 724 metastasis, 813 Bilharziasis. See Schistosomiasis. Celiac artery, anatomy of, 300 Biliary cirrhosis, primary, prostaglandins Central nervous system, tumors of, in in, 399-400 Turcot’s syndrome, 795 Biliary colic, in ascariasis, 564, 566 Cercaria, of Schistosoma, 601, 603 Biliary tract, ascariasis of, 563-572 Cestodes. See Echinococcosis; Tapeworms. clonorchiasis of, 627-631 Chagas’ disease. See Trypanosomiasis, motility disorders of, macrolides in, 229 American. opisthorchiasis of, 627-631 neuropathy in, colonic, 189 Binomial symptom index, in esophageal, 188 gastroesophageal reflux, 69 Chemoprevention, 821-857 Biofeedback, in motility disorders, 238-240 biomarkers in, 824 Biomarkers, in chemoprevention, 824-825 carcinogenesis stages and, 823-824 Bithionol, in fascioliasis, 632 definition of, 822 Bleeding, gastrointestinal, in of colorectal cancer, animal studies of, schistosomiasis, 609, 616-617 825-827 Blood flow, gastric. See Stomach, anti-inflammatory drugs in, 828-834. microcirculation of. See also under Nonsteroidal anti-in- Blood flukes, Schistosoma, 599-625 flammatory drugs. Body habitus, colorectal cancer risk and, antioxidants in, 835 725-726 calcium in, 834-835 Bradykinin, in chloride secretion dietary in, 845-846 regulation, 271-272 difluoromethylornithine in, 41-843 Brain tumors, in Turcot’s syndrome, 795 ellagic acid in, 844-845 862 CUMULATIVE INDEX 1996 Chemoprevention (Continued) manometry of, 152 oltipraz in, 843-844 motility disorders of, 154-159. See also principles of, 823-825 Constipation; Diarrhea; Irritable bowel strategies for, 822 syndrome. Chemotherapy, for colorectal cancer cisapride in, 227 micrometastasis, 815-817 in constipation, 175-176 myenteric plexus damage in, 190 in inflammatory disease, 158 Chest pain, noncardiac. See Noncardiac in pediatric patients, 216-220 chest pain. macrolides in, 229 Chloroquine, in malaria prevention, 458 octreotide in, 231 Chlorpromazine, myenteric plexus damage stress in, 28-29 from, 190 treatment of, 158-159 Cholangitis, in ascariasis, 566, 570-571 motility of, 147-162 in opisthorchiasis, 630 assessment of, 149-154 Cholecystectomy, colorectal cancer risk in, in pediatric patients, 206 729 paradoxic, 156 Cholecystitis, acalculous, in ascariasis, 566 physiology of, 148-149 in cryptosporidiosis, 694 regulation of, 149 Cholecystokinin-receptor antagonists, in response to eating, 149 motility disorders, 232 neuropathy of, 189-190, 195-197 Cholera, in travelers, 457-458 NSAID injury of, 291-293 Chronic idiopathic intestinal pseudo- physiology of, eicosanoids in, 271-272 obstruction, in pediatric patients, 213, polyps of. See also Familial adenomatous 215-216 polyposis. psychopathology of, 23 in attenuated adenomatous polyposis stress in, 27 coli, 795-796 Cimetidine, in gastroesophageal reflux, sulindac ~ _2cts on, 784-785 80-81, 90-91 types of, 738 in NSAID injury prevention, 289 sensation in, 154 Cimetropium, in motility disorders, Colorectal cancer, animal models of, 233-234 825-827 Circulation, of stomach. See Stomach, chemoprevention of, 821-857. See also -microcirculation of. under Nonsteroidal anti-inflammatory Cisapride, in gastroesophageal reflux, 80 drugs. in motility disorders, 225-228 DNA repair system and, 755-772 Clidinium, in motility disorders, 233 eicosanoids and, 273-274 Clonidine, in motility disorders, 234-235 epidemiology of, 717-735 Clonorchiasis, 627-631 familial, 793-803. See also Colorectal can- Colectomy, in familial adenomatous cer, hereditary nonpolyposis; Familial polyposis, 350 adenomatous polyposis. Colitis, in amebiasis, 478, 483-484 clinical characteristics of, 799-800 in trichuriasis, 591 genetic causes of, 800-801 motility disorders in, 158 screening for, 801 ulcerative, cancer risk in, 729 genetic alterations in, 740-749, 763-768, Collagenases, in colorectal cancer 798 metastasis, 811 metastasis and, 814-815 Colon, adenomas of. See also Familial hereditary nonpolyposis, clinical fea- adenomatous polyposis. tures of, 797-798 cancer risk in, 729, 738, 794 colorectal cancer risk in, 729-730 histologic progression of, 738-740 DNA mismatch repair gene mutations in attenuated adenomatous polyposis in, 758-761 coli, 795-796 genetics of, 798 arachidonic acid metabolism in, 325-326 microsatellite instability in, 749-750, enlargement of, in American trypanoso- 761-763 miasis, 526-528 mutations in, DNA mismatch repair familial adenomatous polyposis of. See genes, 763-768 Familial adenomatous polyposis. replication error phenotype of, 798 function of, 147-148 screening for, 799 inflammatory disease of. See Inflamma- histologic progression in, 738-740 tory bowel disease. inhibition of, animal studies of, 825-828 CUMULATIVE INDEX 1996 863 anti-inflammatory drugs in, 828-834. maintenance of, 167-168 See also under Nonsteroidal anti-in- Conversion disorders, vomiting in, 23 flammatory drugs. Cookie swallow, in oropharyngeal antioxidants in, 835 dysphagia, 39 calciurn in, 834-835 Corticosteroids, as cyclooxygenase-2 diet in, 845-846 inhibitors, 366-367 difluoromethylornithine in, 841-843 in inflammatory bowel disease, 328 ellagic acid in, 844-845 NSAIDs with, toxicity of, 387 nonsteroidal anti-inflammatory drugs Costs, of NSAID-induced injury, 388-391 in. See Nonsteroidal anti-inflamma- Cough, in gastroesophageal reflux, 94 tory drugs, in colorectal cancer inhibi- Cricopharyngeal achalasia, 42-43, 46 tion. Cricopharyngeal bar, oropharyngeal oltipraz in, 843-844 dysphagia and, 42 metastasis of, 805-820 Cricopharyngeal muscle, dilation of, in adhesive interactions in, at primary oropharyngeal dysphagia, 46 site, 808-810 myotomy of, in oropharyngeal dyspha- at target organ, 811-814 gia, 46 adjuvant therapy for, 815-817 Crohn's disease, cancer risk in, 729 angiogenesis in, 806-808 neuropathy in, 194 DCC protein role in, 745 Cryptosporidiosis, in immunodeficiency, invasive ability in, 810-811 691-697 microenvironment of, 814 Curcurmin, in colorectal cancer inhibition, process of, 805-806 833-834 suppressor genes for, 814-815 Cyclooxygenase(s), in carcinogenesis, 357 microsatellite instability in, 749-750, in colorectal cancer, 273-274 761-763 in eicosanoid synthesis, 268-270 oncogenes in, 747-749 inhibition of, mucosal injury in, 282-284 pathogenesis of, 737-754, 774 vs. NSAID type, 287-288 polyps in, malignant potential of, 738 inhibitors of. See also Nonsteroidal anti-in- prevention of, 773-791, 821-857 flammatory drugs. NSAIDs in. See Nonsteroidal anti-in- mechanism of action of, colorectal can- flammatory drugs. cer prevention and, 786-787, 829- progression of, 749-750 830 risk factors for, 717-735 isoforms of, 268 dietary, 720-725 Cyclooxygenase-1, 351 inherited, 729-730 action of, 268-270, 364-365 lifestyle, 725-728 deficiency of, 274 medical conditions, 729 in inflammation, 272 screening for, 801 in prostaglandin synthesis, 319-321 in familial adenomatous polyposis, inhibition of, mucosal injury in, 282 797 subcellular distribution of, 270 in hereditary nonpolyposis type, 799 survival rate for, 719 vs. cyclooxygenase-2, 364-365 Computed tomography, in echinococcosis, Cyclooxygenase-2, 351, 363-372 666 action of, 268-270, 365-366 Computer equipment, for esophageal pH deficiency of, 274 monitoring, 64-65 discovery of, 365-366 Concentration methods, for stool distribution of, in gastrointestinal tract, examination, in parasitic disease, 369-370 439-440 in colorectal neoplasia, 273-274 Constipation, causes of, 174-176 in inflammation, 272, 368-369 epidemiology of, 10-11 in prostaglandin synthesis, 319-321 evaluation of, 174-175 inhibition of, mucosal injury in, 282 in American trypanosomiasis, 526-528 selective, 366-370 in Parkinson’s disease, 195 subcellular distribution of, 270 in pediatric patients, 216-218 vs. cyclooxygenase-1, 364-365 physiology of, 154-156 Cyclosporine, nephrotoxicity of, psychopathology of, 26 prostaglandin protection from, treatment of, 158-159 401-403 Continence, fecal, defecation mechanism Cyst(s), of Echinococcus. See Echinococcosis, and, 169 cystic. 864 CUMULATIVE INDEX 1996 Cyst(s) (Continued) Difluoromethylornithine, in colorectal of Giardia, 495, 497-498, 505-506, 508 cancer inhibition, 841-843 Cysticercosis, 641 Diphtheria, immunization for, in travelers, Cytochromes P-450, in eicosanoid 461 synthesis, 268 Diphyllobothrium (fish tapeworm), 644-647 Cytokines, abrogation of, NSAIDs in, 830 Dipylidium caninum (dog tapeworm), Cytomegalovirus infections, gastric 649-650 motility disorders in, 130 Diquat poisoning, liver injury in, Cytoprotection, 279-298 isoprostane measurement in, 418-419 adaptive, 280 Dithiolthiones, in colorectal cancer cyclooxygenases in, 364-365, 369-370 inhibition, 843-844 drug therapy for, 289-290 Diverticulum, Zenker’s, oropharyngeal gastric microcirculation and. See Stom- dysphagia and, 42 ach, microcirculation of. DNA, mismatch repair system of, 755-772 mechanisms of, 280-281 function of, 756-761 NSAID therapy and, cotherapy effects in colorectal cancer, 749-750, 761-768 on, 289-290 gene mutations in, 763-768, 798 injury risk and, 285-288 microsatellite instability in, 761-763 preventive strategies, 285-290, 293 Dog tapeworm, 649-650 toxicity mechanisms in, 281-284 Dogiel neurons, 186 treatment strategies, 290-291, 293 Dorsal horn neurons, second-order, prostaglandins in, 273 252-253 Doxycycline, in malaria prevention, 458 Drugs, in visceral sensation modulation, 256 DCC gene, mutations of, colorectal cancer myenteric plexus damage from, 190-191 in, 744-745 Duodenum, polyps of, upper in colorectal cancer metastasis, 810 gastrointestinal, 794 Defecation, efficiency of, in constipation, DuP 697 (cyclooxygenase-2 inhibitor), 367 175 Dwarf tapeworm, 647-649 in pediatric patients, 206 Dysentery, in trichuriasis, 591 mechanism of, 169 Dyspepsia, functional, 103-112 obstructed, 176-177 causes of, 105-108 proctography during, in incontinence, description of, 103 172 diagnosis of, 109-110 Dehydroemetine, in amebiasis, 483-484 dysmotility-like, 104-105 Descending perineum syndrome, 177 epidemiology of, 8-9 Desmoid tumors, in familial adenomatous natural history of, 12 polyposis, 794-795 psychopathology of, 22 Developing countries, travel to. See reflux-like, 104 Travelers’ diseases. stress in, 27 Dexamethasone, as cyclooxygenase-2 subclassification of, 105 inhibitor, 366-367 treatment of, 108-111 Diabetes mellitus, gastric motility ulcer-like, 104 disorders in, 126-127 nonulcer, 127, 213 travelers’ diseases in, 463 NSAID-induced, 381-382 Diarrhea, epidemiology of, 11 Dysphagia, esophageal function testing in, in amebiasis, 478 52-53 in capillariasis, 584 in American trypanosomiasis, 524 in cryptosporidiosis, 694-697 in gastroesophageal reflux, 76 in giardiasis, 500-503, 506-508 oropharyngeal, 35-50 in isosporiasis, 698 aging and, 43-44 in trichuriasis, 591 anatomic considerations in, 35-36 loperamide in, 232-233 clinical features of, 38 physiology of, 156-157 diagnosis of, 38-42 travelers’, 451-453 manometry in, 36-37, 39-42 treatment of, 159 multidisciplinary swallowing center Dicylomine, in motility disorders, 233 in, 46-48 Diet, colorectal cancer risk and, 720-725, pathophysiology of, 37-38 845-846 physiology of, 35-37 CUMULATIVE INDEX 1996 865 treatment of, 4448 Electrogastrography, in motility videoradiography in, 36 assessment, 122, 211-212 with cricopharyngeal achalasia, 42-43 Electromyography, in colonic motility with cricopharyngeal bar, 42 assessment, 153-154 with Parkinson’s disease, 44 of pelvic floor, in incontinence, 172 with vertebral osteophyte, 42 Ellagic acid, in colorectal cancer inhibition, with Zenker’s diverticulum, 42 844-845 Dysphagia pneumonitis, 86 Encephalitis, Japanese, in travelers, 459 Endoscopic retrograde cholangiopancreatography, in ascariasis, 564 Ear problems, gastroesophageal reflux Endoscopy, in gastroesophageal reflux, 77, and. See Gastroesophageal reflux, ear, 88, 95 nose, and throat problems and. Endothelial cells, cytoprotective effect of, Echinococcosis, 655-689 281 alveolar, 671-683 Endotoxin, in cyclooxygenase-2 induction, causative agent of (Echinococcus multi- 367 locularis), 655-657 Entamoeba dispar, 472-473, 484-485 clinical features of, 675 Entamoeba histolytica. See Amebiasis, diagnosis of, 675-678 causative agent of. epidemiology of, 671-673 Enteric coating, of NSAIDs, efficacy of, geographic distribution of, 671-673 284, 288 immunity to, 673 Enteric nervous system, 183-201 localization of, 673-675 neuropathy of, drug-induced, 190-191 treatment of, 678-683 histochemical studies in, 191-197 cystic, 658-671 in colon, 189-190, 195-197 causative agent of (Echinococcus granu- in esophagus, 188, 191-194 losus), 655-658 in rectum, 189-190 clinical features of, 663-665 in small intestine, 188-189, 194 diagnosis of, 665-667 in stomach, 188, 194 epidemiology of, 658 mast cells in, 197 geographic distribution of, 658-659 silver staining studies in, 187-191 localization of, 658, 660-662 secondary, 658, 660 organization of, 183-185 treatment of, 667-671 structure of, light microscopic studies of, of lung, 665-666, 676 185-187 Echinostomiasis, 634-635 Enterobiasis, 579-583 Eicosanoids, 267-277. See also Leukotrienes; Enterogastric reflux, dyspepsia in, 106 Prostaglandin(s); Thromboxanes. Enteropathy, NSAID, 291-293 biosynthesis of, pathways for, 267-270 Epigastric pain, in functional dyspepsia, cyclooxygenase deficiency and, 274 104 cytoprotective action of, 273 Epithelial cells, cytoprotective effect of, 281 in colorectal neoplasia, 273-274 Erythromycin, in motility disorders, in gastric physiology, 270-271 228-229 in inflammation, 272-273 Escherichia coli, DNA mismatch repair in intestinal physiology, 271-272 system of, 757-758 inflammatory bowel disease and, 317- Esophagitis, epidemiology of, 6 332 in gastroesophageal reflux, 76 in pathogenesis, 319-326 Esophagography, in gastroesophageal inhibition of, 326-329 reflux, 77, 87-88 Eicosapentaenoic acid, in inflammatory Esophagus, achalasia of. See Achalasia. bowel disease, 328 alkaline pH events in, 67 Elderly persons, oropharyngeal dysphagia cancer of, NSAID inhibition of, 343 in, 38 diffuse spasm of, manometry in, 61-62 swallowing in, 43-44 dysfunction of, in American trypanoso- Electrical impedance methods, in gastric miasis, 523-526 motility assessment, 121-122 irritable, chest pain in, 7 Electrical recording, in small intestinal lower sphincter of, manometry of, 56, motility assessment, 123 59-60 Electrodes, for esophageal pH monitoring, luminal pressure sensing in, 55-56 63-64 manometry of, 36-37, 39-42, 55-62 866 CUMULATINIDEVX E19 96 Esophagus (Continued) with Zenker’s diverticulum, 42 ambulatory recording devices for, 5 Ethyl acetate method, for parasite diagnostic interpretation of, 60-62 concentration, in stool examination, equipment for, 55-57 439-440 in achalasia, 60-61 Exercise, colorectal cancer risk and, in diffuse esophageal spasm, 61-62 726-727 in gastroesophageal reflux, 77-78, 88 for swallowing efficiency, 45 in lower sphincter relaxation measure- with biofeedback, in motility disorders, ment, 59-60 238-240 : in nonspecific motor defect, 62 in peristalsis evaluation, 58-59 in swallowing monitoring, 58 low-compliance infusion pumps for, Familial adenomatous polyposis, 349-361 oy attenuated adenomatous polyposis coli luminal pressure sensing in , J5O5 -56 variant of, 795-796 recording devices for, 57 cancer development in, 729-730, 739 APC gene mutations in, 740-742 sphincter function and, 56 clinical features of, 794-795 motility disorders of, cisapride in, 226- description of, 349-350 227 Gardner’s syndrome variant of, 795 function testing in, 51-73 genetics of, 796 fluoroscopy in, 53-55 NSAID-induced polyp reduction in, 334, in gastroesophageal reflux, 76-79, 776-778 84-88, 94-95 animal studies of, 352-353 indications for, 52-53 clinical trials of, 353-356, 832-833 manometry in. See Esophagus, ma- mechanism of, 357-358 nometry of. screening for, 797 pH monitoring in, 63-69 Turcot’s syndrome variant of, 795 role of, 51 variants of, 795-796 macrolides in, 229 Familial risk, of colorectal cancer, 793-803. psychopathology of, 21-22 See also Colorectal cancer, hereditary stress in, 26-27 nonpolyposis; Familial adenomatous neuropathy of, 188, 191-194 polyposis. nonspecific motor defect of, manometry clinical characteristics of, 799-800 in, 62 genetic causes of, 800-801 nutcracker, psychopathology of, 22 screening for, 801 pH monitoring of, 63-69 Famotidine, in gastroesophageal reflux, analysis of, 66-69 80-81 applications of, 69 in NSAID injury prevention, 289 equipment for, 63-65 Fascioliasis, 631-632 in gastroesophageal reflux, 78-79, 85, Fasciolopsiasis, 633-634 88, 95 Fat, dietary, colorectal cancer risk and, technique for, 65-66 723-724, 846 structure defects of, fluoroscopy of, Fatty acids, N-3, in inflammatory bowel 53-54 disease, 328 upper sphincter of, function testing of, unsaturated, in fish oil, colorectal cancer 52 risk and, 724-725 high-pressure zone of, 35 Feces examination. See Stool examination. manometry of, 56 Fed pattern, in gastrointestinal motility, oropharyngeal dysphagia and, 35-50 1S; 27 anatomy of, 35 Fedotozine, in motility disorders, 235 diagnostic assessment of, 38-42 Fenretinide, in colorectal cancer inhibition, manometry in, 36-37, 39-42 Q24 physiology of, 35-36 Fiber, dietary, colorectal cancer risk and, treatment of, 44-48 720-721, 846 videoradiography of, 36 Fibroblast growth factor, basic, in cancer with cricopharyngeal achalasia, metastasis, 807 42-43 Filariform larvae, of Strongyloides with cricopharyngeal bar, 42 stercoralis, 699 with Parkinson’s disease, 44 Fish, in disease transmission, capillariasis, with vertebral osteophyte, 42 583-584 CUMULATIVE INDEX 1996 867 opisthorchiasis, 627-631 Gastric secretion, regulation of, Fish oil, colorectal cancer risk and, 724-725 prostaglandins in, 271 in inflammatory bowel disease, 328 Gastrocolic reflex, 149 Fish tapeworm, 644-647 Gastroenteropathy, diabetic, 127 FLAP (5-lipoxygenase-activating protein), Gastroenterostomy, gastric motility 321-324 disorders in, 126-127 inhibitors of, in inflammatory bowel dis- Gastroesophageal reflux, 75-102 ease, 327 asthma and, 86-91 Flap valve theory, of fecal continence, clinical features of, 87 167-168 esophageal testing in, 87-88 Flotation method, for parasite treatment of, 88, 90-91 concentration, in stool examination, clinical features of, 76 439-440 asthma and, 87 Flukes, blood, Schistosoma, 599-625 ear, nose, and throat problems and, intestinal, 632-635 93-94 liver, 627-632 noncardiac chest pain and, 84 Fluoride, colorectal cancer risk and, 723 ear, nose, and throat problems and, Fluoroscopy, in esophageal function 91-97 testing, 53-55 clinical features of, 93-94 5-Fluorouracil, in colorectal cancer esophageal testing in, 94-95 micrometastasis, 815-817 treatment of, 95-97 Flutter valve theory, of fecal continence, epidemiology of, 5-7 168 esophageal testing in, 76-79 Folate, colorectal cancer risk and, 722-723 asthma and, 87-88 Food, precautions with, in giardiasis ear, nose, and throat problems and, prevention, 508-509 94-95 in travel, 464, 485 noncardiac chest pain and, 84-85 Food-borne diseases, amebiasis, 471 fluoroscopy in, 54-55 in travelers, 451-458, 464, 485 globus sensation with, 7 tapeworms, beef, 638-644 in functional dyspepsia, 104 dwarf, 647-649 in gastric motility disorders, 129-130 fish, 644-647 noncardiac chest pain and, 81-86 pork, 638-644 clinical features of, 84 rodent, 649 esophageal testing in, 84-85 Free radicals, isoprostanes as index for. treatment of, 85-86 See Isoprostanes. pH monitoring in, 63-69 Fruits, anticarcinogenic agents in, physiologic, 75 colorectal cancer risk and, 721-723, quantification of, 67-68 845 stress in, 27 Functional dyspepsia. See under Dyspepsia. symptom analysis in, 68-69 Functional gastrointestinal disorders. See treatment of, 79-81 Motility, disorders of. asthma and, 88, 90-91 Furazolidone, in giardiasis, 506-508 ear, nose, and throat problems and, 95-97 noncardiac chest pain and, 85-86 Gastrointestinal tract, megasyndrome of, 8-Galactoside lectins, in colorectal cancer in American trypanosomiasis, 523-529 metastasis, 813-814 Gastroparesis. See Gastric emptying, delayed. Gallbladder, motility disorders of, Gender, vs. NSAID injury risk, 384 cisapride in, 227 Genes, mutations of, in colorectal cancer, Gardner’s syndrome, 795 740-749 Gastric. See also Stomach. DNA mismatch repair type, 763-768 Gastric acid, reflux of. See Gastroesophageal metastasis and, 814-815 reflux. in familial adenomatous polyposis, Gastric emptying, assessment of, 120-122 796 delayed, 125-126 in hereditary nonpolyposis colorectal idiopathic, 127-128 cancer, 798 in functional dyspepsia, 104-106, 110 Giardiasis, 493-515 in pediatric patients, 212 acute, 503 physiology of, 115-116, 118-119 asymptomatic, 502-503 868 CUMULATIVE INDEX 1996 Giardiasis (Continued) Hirschsprung’s disease, in pediatric causative agent of (Giardia), 494-496 patients, 219-220 identification of, 505-506 neuropathy in, 189-190, 195 chronic, 5C3 Histamine-2 blockers, in gastroesophageal clinical features of, 502-504 reflux, 80-81 complications of, 503-504 in NSAID injury prevention, 289 diagnosis of, 504-506 HIV infection. See Human immunodeficiency epidemiology of, 496-498 virus infection. pathogenesis of, 500-502 hMLH genes, in hereditary nonpolyposis pathology of, 498-500 colorectal cancer, 758-761, 763-768, prevention of, 508-509 798 transmission of, 497-498 hMSH genes, in hereditary nonpolyposis treatment of, 506-508 colorectal cancer, 758-760, 763, Globus sensation, epidemiology of, 7 766-768, 798 in gastroesophageal reflux, 94 Hoarseness, in gastroesophageal reflux, 93 Gonadotropin-releasing hormone analogs, Hookworm infections, 585-588 in motility disorders, 231 Hormones, colorectal cancer risk and, Granuloma, in visceral leishmaniasis, 542 727-728 Human immunodeficiency virus infection, Growth retardation, in ascariasis, 558-559 amebiasis in, 473 in giardiasis, 503-504 cryptosporidiosis in, 691-697 in trichuriasis, 591-592 giardiasis in, 497 Guanosine triphosphate and guanosine isosporiasis in, 697-699 diphosphate, K-ras proto-oncogene strongyloidiasis, 702 interactions with, in colorectal cancer, travelers’ diseases in, 463-464 748-749 visceral leishmaniasis in, 541 Hydatid disease. See Echinococcosis. Hydrogen breath tests, of small intestinal H; blockers, in gastroesophageal reflux, motility, 123 80-81 5-Hydroxytryptamine antagonists, in Heart disease, in American motility disorders, 230 Hymenolepsis diminuta (rodent tapeworm), trypanosomiasis, 521-523 649 travelers’ diseases in, 463 Hymenolepsis nana (dwarf tapeworm), Heartburn, in gastroesophageal reflux, 5-6, 647-649 75-76 Hyoscyamine, in motility disorders, 233 Helicobacter pylori, in functional dyspepsia, Hypersensitivity, in giardiasis, 504 9, 107 visceral, dyspepsia in, 106-107, 110 NSAID ulcer development and, 286, Hypertension, portal, in schistosomiasis, 387-388 609-610 Helminths, Ancylostoma caninum, 585-588 Hypnosis, in motility disorders, 240-241 Ascaris lumbricoides, 553-577 Capillaria, 583-585 detection of, in stool specimen, 443 Echinococcus, 655-689 Ibuprofen, in colorectal cancer inhibition, Enterobius vermicularis, 579-583 animal studies of, 774-775 hookworms, 585-588 injury from, risks of, 385 Necator americanus, 585-588 Ileus, 130-131 Trichuris trichiura, 588-593 Illness behavior, childhood learning of, Hepatitis, viral, liver injury in, motility disorders and, 29 prostaglandin protection from, Immune response, in cryptosporidiosis, 398-399 695 Hepatitis A, in travelers, 453-456 in echinococcosis, 673 Hepatitis B, in travelers, 460 in leishmaniasis, 540-541 Hepatorenal syndrome, isoprostane in schistosomiasis, 610-611 measurement in, 422 in strongyloidiasis, 701 Hereditary nonpolyposis colorectal cancer. Immunity, in amebiasis, 477-478 See under Colorectal cancer. Immunization, for amebiasis, 484-485 Herpes simplex virus infections, gastric for giardiasis, 508-509 motility disorders in, 130 for travelers. See specific diseases under Heterophyiasis, 634 Travelers’ diseases.